Columbia aims to revolutionize pharmacology by delivering a high resolution precision monitoring system that can be used in large populations to assess drug efficacy and in individuals to tailor…

Columbia aims to revolutionize pharmacology by delivering a high resolution precision monitoring system that can be used in large populations to assess drug efficacy and in individuals to tailor optimal drug treatment. Their grand vision is to enable the transformation of clinical therapeutics to dramatically enhance capabilities to manage disease substantially improve therapeutic benefits to patients by delivering precision therapeutics and maximize benefit to pharmaceutical suppliers through the ability to anticipate and reduce adverse therapeutic effects.specifically the indipharm team proposes to 1) automate the identification of thousands of FDA approved drugs drug metabolites chemicals that modify drug metabolism and drug impurities. 2) utilize and validate the mass spectrometry platform in highly phenotyped cohorts by merging pharmacogenomic and pharmacoexposomic data. 3) deliver multi modal network and artificial intelligence based models to predict drug efficacy by integrating large scale pharmacogenomic and pharmacoexposomic data. 4) deliver a database software infrastructure to house chemical libraries that facilitate the identification of tens of thousands of drugs chemicals and metabolites. 5) develop combined pharmacogenomic pharmacoexposomic models for optimizing drug therapies in individuals and populations. 6) scale the mass spectrometry platform for application to large population studies (greater than 100000 participants) and for a range of clinical settings to ensure widespread access. Together these goals will lead to transformative changes in the therapeutic landscape provide improved therapy to patients in an equitable manner and help alleviate unnecessary human suffering. Subrecipients are brown university emory university public health emory university medicine harvard jackson laboratory mayo clinic